Familial Amyloidosis: Great Progress for an Orphan Disease | oneAMYLOIDOSISvoice
×
Or register here
Global Search

Trusted Resources: Education

Scientific literature and patient education texts

Back to Education / Scientific Articles

Familial Amyloidosis: Great Progress for an Orphan Disease

key information

source: Journal of Hepatology

year: 2014

authors: Barreiros AP, Otto G, Kahlen B, Teufel A, Galle PR

summary/abstract:

Familial amyloidosis (synonym for familiar amyloid polyneuropathy [FAP]) is an autosomal dominant inherited disease, caused by mutations in the transthyretin (TTR) gene, coding for the corresponding protein consisting of 127 amino acids. It was first described by the Portuguese neurologist Andrade. The TTR gene is located on chromosome 18q. More than 100 different mutations are known. The most common mutation is the Val30Met mutation, endemically found in Portugal, Sweden, and Japan. Among the other mutant proteins that are of etiological importance but are very rare, is apolipoprotein I and II, or fibrinogen A.

Transthyretin is a tetramer, built out of four identical TTR-subunits. Point mutations of the gene lead to a destabilization of the protein and subsequently to protein misfolding, resulting in the extracellular deposition of mutated amyloid in several tissues, predominantly in peripheral/autonomic nerves, gastrointestinal tract and myocardium.

organization: Universitätsmedizin of the Johannes Gutenberg-University Mainz, Germany; Universitätsklinikum of the University Regensburg, Germany

DOI: 10.1016/j.jhep.2014.09.008

read more full text

Related Content

To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences.
More information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close

Community Key Collaborator

Support for this landing page is provided by an independent education grant from

Translation of this platform made possible through an independent education grant from

© 2025 rareLife solutions Inc.

To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences.
More information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close